ICHNO-ECHNO 2022 - Abstract Book

S26

ICHNO-ECHNO 2022

Digital Posters

Poster: Epidemiology and prevention

PO-0054 Exosomal serum biomarkers as predictors for laryngeal carcinoma

S. Mueller 1 , O. Wendler 1 , J. Schuster 1 , H. Iro 1

1 University of Erlangen-Nürnberg, Otolaryngology, Erlangen, Germany

Purpose or Objective Laryngeal carcinomas are the third most common head and neck cancer. Whereas glottic carcinomas present themselves relatively early with voice changes, especially localizations in the supra- and subglottic regions lead to locally advances carcinomas at the time of diagnosis in about 40% of the cases. Currently, there is no screening method and diagnosis is difficult and can only be made by laryngoscopy. Thus, the objective of this study was to identify exosomal serum biomarkers that can diagnose laryngeal carcinomas and distinguish between early and late stages. Materials and Methods IRB approved single center study of n=14 patients with laryngeal carcinomas (Stage I, Stage IV) and n=7 controls who all underwent a panendoscopy for tumor staging and biopsy. A multiplexed proteomic array (n=2000 proteins) on exosomes isolated from serum collected at the day before surgery was performed. The most promising proteins for diagnosis and differentiation were calculated using biostatistical methods and were validated using Western Blots and Immunohistochemistry. Results TIE-1 (fold change (FC) 6.3) was the best protein to distinguish between any stage of laryngeal carcinoma and control patients. PKLR (FC 10.2) was the most underexpressed protein in Stage IV compared to Stage I whereas SOX 17 (FC 9.2) was the most overexpressed. Conclusion TIE-1, PKLR and SOX17 have been identified as potential novel biomarkers for the diagnosis of laryngeal carcinoma as well as differentiation between different stages. Further studies are needed to validate these results. 1 Copenhagen University Hospital, Rigshospitalet, Department of Oncology, Copenhagen, Denmark; 2 Copenhagen University Hospital, Herlev, Department of Oncology, Herlev, Denmark; 3 Copenhagen University Hospital, Rigshospitalet, Department of Oncology, Rigshospitalet, Denmark Purpose or Objective In patients with head and neck squamous cell carcinoma (HNSCC), curative-intent radiotherapy (RT) and chemoradiotherapy (CRT) are associated with substantial acute morbidity and 5–10% of patients die within 180 days of treatment initiation. Most of these early deaths occur without HNSCC recurrence or progression and may therefore be preventable to some extent. We developed a prediction tool to estimate the risk of non-HNSCC mortality occurring within the first 180 days following RT/CRT initiation. Materials and Methods Patients with HNSCC treated with RT/CRT, including postoperative RT/CRT, at Rigshospitalet or Herlev Hospitals between 2010–2017 were identified in the Danish Head and Neck Cancer Group (DAHANCA) database. Predictor variables included age, stage, performance status, tumor subsite including p16 status, comorbidity, postoperative status, smoking and pre- treatment albumin levels. The 180-day non-HNSCC mortality risk was estimated by combining cause-specific Cox regression models. Results We included 2209 patients. The 180-day non-HNSCC mortality rate was 4.4% and almost one third (31.6%) of non- HNSCC deaths were caused by pneumonia. After internal model validation, the area under the receiver operating curve was 0.74 (95% CI: 0.66–0.81) and calibration was good for risk predictions ranging from 0–20%. Conclusion We developed a prediction tool to estimate the 180-day non-HNSCC mortality risk. This tool can be used to select high-risk patients for supportive interventions aiming to improve survival rates, and is available for interactive use at https://emriskpred.shinyapps.io/EMNED_App/. PO-0055 Early non-cancer mortality risk prediction after definitive radiotherapy in Head and Neck Cancer K.H. Jensen 1 , I.R. Vogelius 1 , C.A. Kristensen 1 , C. Maare 2 , E. Andersen 2 , L. Specht 1 , A. Gothelf 1 , M. Bernsdorf 3 , J. Friborg 1

PO-0056 Predicting factors for the development of malignant tumors of the paranasal sinuses and nasal cavity

M. Makarevich 1 , Z. Kolyadich 1 , A. Evmeneko 2